Patients with asthma and chronic rhinosinusitis with nasal polyps derive greater benefit from dupilumab as eosinophil and fractional exhaled nitric oxide levels increase.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/high-type-2-biomarkers-identify-patients-most-likely-benefit-2026a1000khc?src=rss
Author :
Publish date : 2026-06-17 13:43:00
Copyright for syndicated content belongs to the linked Source.
